3 Things You Should Know About Interventional Glaucoma Comanagement
Jun 04, 02:42 PM
Share
Subscribe
Glaucoma is a leading cause of irreversible blindness and affects approximately 80 million people globally, with projections to exceed .111 million by 2040. We know that the elevated intraocular pressure is the key modifiable risk factor which is why reducing intraocular pressure is central to treatment strategies.
In this podcast, expert faculty from the featured symposium at the 2025 EnVision Summit share insights about interventional glaucoma co-management.
Those faculty include ophthalmologists Rachel Simpson from Moran Eye Center in
Salt Lake City, UT; James Murphy from Connecticut Eye Physicians in New Haven, CT; Mary Qiu from the Cleveland Clinic’s Cole Eye Institute in Cleveland, Ohio; and optometrist Jessica Steen from the Nova Southeastern University College of Optometry in Fort Lauderdale, FL.
In this podcast, expert faculty from the featured symposium at the 2025 EnVision Summit share insights about interventional glaucoma co-management.
Those faculty include ophthalmologists Rachel Simpson from Moran Eye Center in
Salt Lake City, UT; James Murphy from Connecticut Eye Physicians in New Haven, CT; Mary Qiu from the Cleveland Clinic’s Cole Eye Institute in Cleveland, Ohio; and optometrist Jessica Steen from the Nova Southeastern University College of Optometry in Fort Lauderdale, FL.